What's new

EMEA-003174-PIP01-21-M01

EMEA-003174-PIP01-21-M01

Feb 13, 2025 - 17:01
 0
EMEA-003174-PIP01-21-M01
EMEA-003174-PIP01-21-M01
Read More

Tags:

Previous Article

Nissan’s contribution to Renault Group’s – Full year 2024 earnings: €211 million

Next Article

Human medicines European public assessment report (EPAR): Dimethyl fumarate Neur...

Related Posts

Withdrawn application: Dupixent, 18/02/2025

Withdrawn application: Dupixent, 18/02/2025

Feb 28, 2025  0

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 67, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0